MARKET

PRTK

PRTK

Paratek Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.570
+0.180
+4.10%
After Hours: 4.550 -0.02 -0.44% 16:35 05/22 EDT
OPEN
4.430
PREV CLOSE
4.390
HIGH
4.700
LOW
4.430
VOLUME
597.04K
TURNOVER
--
52 WEEK HIGH
5.89
52 WEEK LOW
2.500
MARKET CAP
193.94M
P/E (TTM)
-1.3068
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRTK stock price target is 15.00 with a high estimate of 34.00 and a low estimate of 6.00.

EPS

PRTK News

More
Paratek Plods Along
Seeking Alpha - Article · 05/14 01:02
Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and militar
GlobeNewswire · 05/11 20:05
Paratek Pharmaceuticals, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/11 18:54
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/11 18:45
Paratek Pharmaceuticals: Q1 Earnings Insights
Benzinga · 05/11 12:14
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 11:55
Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
GlobeNewswire · 05/11 11:30
Paratek Pharmaceuticals: Q1 Earnings Insights
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 40.00% year over year to ($0.66), which beat the estimate of ($0.80).
Benzinga · 05/11 11:14

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About PRTK

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
More

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.